Latest daily commentaries
View the latest research daily commentaries and high level analysis, including morning and eveing flash notes and regular updates on company events and macro economic themes.
Northland Capital Partners Morning Report
19 May 16
After today’s announcement, ValiRx is a step closer to commencing its second clinical programme, VAL401. With manufacturing lined up, sufficient clinical trial supplies should soon be ready to commence dosing patients. Due to VAL401’s established safety profile, ValiRx expects to fast-track the programme straight into a Phase 2b trial.